Table 2 Survey responses for MSI testing in academic and nonacademic institutions
Overall, N = 96 | Academic, N = 59 | Nonacademic, N = 37 | |
|---|---|---|---|
Universal screening | |||
Resection | 76 (79%) | 49 (83%) | 27 (73%) |
Biopsy | 56 (58%) | 35 (59%) | 21 (57%) |
Extra-colonic GI cancer | 10 (10%) | 9 (15%) | 1 (3%) |
Initial screening methodology | |||
IHC on MMR proteins only | 73 (76%) | 39 (66%) | 34 (92%) |
DNA-PCR only | 2 (2%) | 2 (3%) | 0 (0%) |
Both | 17 (18%) | 16 (27%)* | 1 (3%)* |
Subsequent testing for MLH1/MSH2 loss | |||
BRAF mutation | 60 (64%) | 37 (63%) | 23 (66%) |
MLH1 hypermethylation | 12 (13%) | 7 (12%) | 5 (14%) |
Both | 12 (13%) | 9 (15%) | 3 (9%) |
Incorporation into histology grade | |||
Yes | 23 (24%) | 14 (24%) | 9 (25%) |
No | 72 (76%) | 45 (76%) | 27 (75%) |
